首页> 美国卫生研究院文献>other >Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients

【2h】

Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients

机译：阿瑞匹坦对癌症患者中控释口服羟考酮药代动力学的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeOxycodone is a µ-opioid receptor agonist widely used in the treatment of cancer pain. The predominant metabolic pathway of oxycodone is CYP3A4-mediated N-demethylation to noroxycodone, while a minor proportion undergoes 3-O-demethylation to oxymorphone by CYP2D6. The aim of this study was to investigate the effects of the mild CYP3A4 inhibitor aprepitant on the pharmacokinetics of orally administered controlled-release (CR) oxycodone.

机译：目的羟考酮是一种μ阿片受体激动剂，广泛用于治疗癌症疼痛。羟考酮的主要代谢途径是CYP3A4介导的N-去甲基化为去甲羟可酮，而一小部分通过CYP2D6进行3-O-去甲基化为羟吗啡酮。这项研究的目的是研究轻度CYP3A4抑制剂aprepitant对口服给予控释（CR）羟考酮的药代动力学的影响。

著录项

期刊名称 other
作者
Yutaka Fujiwara; Masanori Toyoda; Naoko Chayahara; Naomi Kiyota; Takanobu Shimada; Yoshinori Imamura; Toru Mukohara; Hironobu Minami;
展开▼
作者单位

展开▼
年(卷),期 -1(9),8
年度 -1
页码 e104215
总页数 7
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain (see comments) [J] . Bruera E, Belzile M, Pituskin E, Journal of Clinical Oncology . 1998,第10期

机译：随机，双盲，交叉试验比较了口服控释羟考酮与吗啡控释在癌症疼痛患者中的安全性和有效性（参见评论）
2. Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl [J] . Leppert Wojciech, Nosek Krzysztof Current pharmaceutical design . 2019,第30期

机译：用口腔控制释放吗啡和羟考酮及透皮丁啡酮和芬太尼治疗癌症患者生活质量的比较
3. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients [J] . Krzysztof Nosek, Wojciech Leppert, Hanna Nosek, Drug Design, Development and Therapy . 2017,第5期

机译：口服控释吗啡和羟考酮与丁丙诺啡和芬太尼透皮制剂治疗癌症严重疼痛的比较
4. EZH2 Promotes Malignant Phenotypes and Is a Predictor of Oral Cancer Development in Patients with Oral Leukoplakia [C] . Wei Cao, Rania H. Younis, Jiang Li, Academic Committee conference of Shanghai key lab of stomatology . 2011

机译：EZH2促进恶性表型，是口腔白斑患者口腔癌发展的预测因子。
5. Evaluation of the pharmacokinetic-pharmacodynamic relationship for the matrix metalloproteinase inhibitory effect of COL-3 following oral administration to patients with refractory metastatic cancer. [D] . Rudek, Michelle Ann. 2001

机译：口服给予难治性转移癌患者后，COL-3对基质金属蛋白酶抑制作用的药代动力学与药效关系的评价。
6. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients [O] . Krzysztof Nosek, Wojciech Leppert, Hanna Nosek, 2017

机译：口服控释吗啡和羟考酮与丁丙诺啡和芬太尼透皮制剂治疗癌症严重疼痛的比较
7. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. [O] . Yutaka Fujiwara, Masanori Toyoda, Naoko Chayahara, 2014

机译：阿瑞吡坦对癌症患者控释口服羟考酮药代动力学的影响。

Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients

摘要

著录项

相似文献

相关主题

期刊订阅